

Alginate-based hydrogels for cancer therapy and research

Belen Reig-Vano^{1*}, Bartosz Tylkowski², Xavier Montané³, Marta Giamberini¹

¹ Department of Chemical Engineering, Universitat Rovira i Virgili, Av. Països Catalans 26, Campus Sescelades, 43007 Tarragona, Spain. belen.reig@urv.cat (B.R.); marta.giamberini@urv.cat (M.G.)

² Eurecat, Centre Tecnològic de Catalunya. Chemical Technologies Unit, Marcel·lí Domingo s/n, 43007 Tarragona, Spain. bartosz.tylkowski@eurecat.org (B.T.)

³ Department of Analytic Chemistry and Organic Chemistry, Universitat Rovira i Virgili, Carrer Marcel·lí Domingo s/n, Campus Sescelades, Tarragona43007, Spain. xaviermontanemontanem@gmail.com (X.M)

* Correspondence: belen.reig@urv.cat Av. Països Catalans 26, Campus Sescelades, 43007 Tarragona, Spain.

Received: 4 October 2020; Accepted: date; Published: date

Declaration of Interest: None.

Abstract: Cancer is a major health issue concerning to all of us. Current treatment options are still limited due to not-selective action. Encapsulation is contemplated as an innovative approach to address systemic toxicity and tumor resistance caused by traditional therapies, while increasing encapsulated compounds bioavailability. The coating material of capsules strongly determines the success of the system. Since alginate has been proved non-toxic, biocompatible and biodegradable, it is considered a potential vehicle for therapeutic factors encapsulation. Besides, it has the particular ability to form hydrogels, which hold a high-water content and greatly resemble to natural soft tissues. The present review exposes the state-of-the-art and the most sophisticated alginate-based systems for cancer therapy and research. It begins with an overview of alginate hydrogels and the qualities that make them especially suitable for biomedical applications. In the following section, the application of alginate hydrogels as pioneering strategies for cancer treatment is described. Several examples of alginate-based delivery systems of therapeutic drugs, proteins and nucleic acids are provided. Significant emphasis is placed in both oral delivery systems and colorectal cancer therapy. Moreover, the role of alginate 3-D scaffolds for both cell culture and delivery is explained. Lastly, other applications of alginate-based hydrogels such as tumor biomarkers immunosensing and fluorescent surgical marker are included.

Keywords: alginate; cancer; chemotherapy; drug delivery; protein delivery; cell encapsulation; 3-D scaffold.


1. Introduction

Cancer is one of the main causes of mortality around the world. The Global Cancer Observatory database of the International Agency for Research on Cancer, which provides incidence and mortality for 36 cancer types in 185 countries, estimated that 9.6 million people worldwide died because of cancer only in 2018. In addition, 18.1 million people were diagnosed for first time and 43.8 million suffered from recurrent cancer within 5 years or less [1,2]. Lung, prostate, colorectal, stomach and liver are the most prevalent cancer types among men, whereas breast, colorectal, lung, cervix and thyroid cancer are the most frequent types among women. Nowadays one in five men and one in six women are diagnosed with cancer throughout their lives [2]. Unfortunately, one in eight diagnosed men and one in eleven diagnosed women will not overcome this illness [3].

The global cancer burden rises in most of countries. The mortality differences between countries with high, low and medium Human Development Index (HDI) are minor: although incidence rate in countries with low and medium HDI is inferior, the survival rate is also lower due to the late detection and limited access to efficient treatments [3]. Current treatments include surgery, immunotherapy, chemotherapy, targeted therapy, hormonal therapy and radiotherapy [2,4]. In spite of favorable results, the non-selective action of these procedures results in severe side effects which seriously compromise patients' welfare. Tumor resistance

1 caused by selective pressure is as well a serious drawback that impedes patients total recovery
2 [4]. Hence, oncological research is making huge efforts so as to address these challenges. In
3 this regard, encapsulation represents a promising strategy [5].

4 Encapsulation is the process of coating solid, liquid or gaseous compounds into a continuous
5 layer or shell, giving rise to beads. Microbeads diameter range from 1 to 1000 μm whereas
6 nanobeads measure from 10 to 1000 nm [6–8]. Beads are called “spheres” if they are spherical
7 matrices with dispersed active compounds within, or “shell/core capsules” if they are composed
8 by a core of a confined compound surrounded by a coating layer or shell (Figure 1) [6–11].



9

10 **Figure 1:** Scheme of beads classification based on encapsulated compound distribution. The
11 active compound is represented in blue. This can be confined in the inner part of the bead forming
12 a core, which is known as shell/core capsule. It can also be dispersed within the bead matrix,
13 which is known as sphere.

14 Encapsulation allows the controlled delivery of encapsulated therapeutic compounds [2,5,12].
15 The release profile strongly depends on the matrix composition. Hence, it determines the
16 success of the delivery system. In order to be used for biomedical purposes, coating material
17 has to compile some fundamental requirements, such as suitable physicochemical
18 characteristics and biocompatibility. Synthetic and natural polymers are typically used for
19 encapsulation purposes [13]. Some of the synthetic polymers that have been employed as
20 delivery systems are: poly lactic acid (PLA) [14], polyglycolic acid (PGA) [15], poly(D,L-lactide-
21 co-glycolide) (PLGA) [16], polyethylene glycol (PEG) [17], poly(vinyl alcohol) (PVA) [18,19],
22 polycaprolactone (PCL) [20], poly(beta-amino esters) (PbAE) [21,22] and ethylene-vinyl acetate
23 (EVA) [23]. Natural polymers employed as coating materials include both polysaccharides such
24 as alginate [24], pectin [25], chitosan [26], cyclodextrins [27], dextran [28], agarose [29],
25 hyaluronic acid [30], carrageenan [31], fucoidan [32], starch [33], polyhydroxybutyrate (PHB)
26 [34] and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) [35], and proteins such as
27 keratin [36], gelatin [37] albumin [38], collagen [39] and gliadin [7,11,24,40].


28 Among natural polymers, polysaccharides are especially valuable for biomedical applications
29 because they are abundant in nature and derive from renewal sources; they exhibit a wide
30 diversity of compositions and structures [40]. They are stable, highly water soluble, non-toxic
31 and biodegradable [6,41]. Owing to these properties among others, this review focuses on
32 alginate. An overview of alginate properties and gelation ability is presented in the next
33 sections.

34 **2. Alginate**

35 **2.1 Chemical structure**

36 Alginate is the generic nomenclature that refers to a family of linear polysaccharides such as
37 alginic acid and alginate salts, composed by $\beta(1\rightarrow4)$ linked β -D-mannuronic acid (M) residues
38 and its C-5 epimer α -L-guluronic acid (G). These monomers are arranged in a non-regular
39 block-wise pattern consisting of homosequences of consecutive M or G residues (M- or G-

1 blocks) alternated with G/M heterosequences (Figure 2) [42–44]. The composition, molecular
 2 weights and hence, material properties of alginate depends on the source of extraction [42–44].



3

4

5

6 **Figure 2:** Representative chemical structure of alginate. $\beta(1\rightarrow4)$ linked β -D-mannuronic acid (M)
 7 and α -L-guluronic acid (G) monomers and schematic representation of M-blocks, G-blocks and
 8 G/M heterosequence.


9 **2.2 Sources and extraction**

10 Alginates are found in a wide range of brown algae such as *Macrocystis pyrifera*, *Laminaria*
 11 *hyperborea*, *Laminaria digitate*, *Laminaria japonica*, *Durvillaea Antarctica*, *Ecklonia maxima*,
 12 *Lessonia nigrescens*, *Sargassum spp.* and *Ascophyllum nodosum* [43,45]. Its molecular weight
 13 goes from 32 to 400 kg/mol [43]. Variability is mainly due to the specie and algae age [6].

14 Alginate biosynthesis is as well performed by two bacterial genera: both *Pseudomonas* and
 15 *Azotobacter* synthesize alginate as an exopolysaccharide [46]. In *P. aeruginosa*, alginate has a
 16 vital role in the configuration of biofilms. Besides, *Azotobacter* employs high G-content alginates
 17 as a part of the resistant desiccation structure of cysts [46]. Generally, bacterial biosynthesis
 18 provides high quality alginate with better characterized structures and properties [45,47].

19 Nowadays, more than 200 types of alginate are commercially available [42]. In spite of the
 20 heterogeneous composition, most of them come from farmed brown seaweeds.

21 Algal alginate extraction starts with the removal of counterions followed by the neutralization
 22 and solubilization of alginic acid through alginate salts generation [10]. Sodium carbonate or
 23 sodium hydroxide are usually employed as alkali compounds, which produce sodium alginate
 24 [48]. Once extracted, alginate formulation presents many impurities such as heavy metals,
 25 proteins, endotoxins and polyphenols (Figure 3) [45]. These contaminants seriously
 26 compromise biocompatibility [43,46]. Ultrapure amitogetic alginates are mandatory for
 27 biomedical applications [14]. For this reason, further extraction and rigorous purification
 28 processes are necessary.



29

30 **Figure 3:** Schema of algal alginate extraction process.

2.3 Alginate gelation

Alginates have the particular gel-forming ability. It can occur either by ionotropic gelation or by acid precipitation [49]. The current review focuses on the former gelation method: ionotropic gelation occurs when negatively charged carboxyl moieties of alginate chains interact with multivalent cations or with cationic polymers [45,50]. Aqueous alginate solution, also referred as “sol” phase, can be cross-linked by both bivalent and trivalent cations [51,52]. Alginate crosslinking gives rise to “sol-to-gel” transition, which results in alginate hydrogels that retain high content of water molecules through hydrogen bonds [53].

Gelation kinetics and features of the obtained hydrogels substantially depend on the ion’s properties, such as the valence and radius [49]. Cations employed as crosslinking agents can be arranged according to their affinity to alginate, as follows: $Mn < Zn, Ni, Co < Fe < Ca < Sr < Ba < Cd < Cu < Pb$ [49]. Alginate interaction with trivalent ions such as Fe and Al is stronger than with divalent ions [49].

The interaction between multivalent cations and alginate is described by the “egg-box” model. It suggests that two G-blocks of adjacent chains form electronegative cavities - “egg box junctions”, which are able to host cations [47]. Normally, “egg box junctions” are occupied by alginate counter-ions, such as sodium in case of sodium alginate [10]. Nevertheless, these can be replaced by multivalent ions whose size and charge also fit in the cavities [50]. As a result of the ion exchange, the “egg box” structure forms (Figure 4) [47]. Although just G-blocks were considered to be involved in intermolecular crosslinking [42], MGM-blocks may also contribute to gelation through weak interactions with cations [45,48].





Figure 4: Schema of alginate “sol-to-gel” and “egg-box” model.

Ionotropic gelation may occur *via* external or internal mechanisms [6]. The difference lies in the source of crosslinking agent and the gelling kinetics (Figure 5). External gelation is based on the diffusion of an external source of multivalent cations. Hydrogels are produced when the alginate “sol” phase, usually in form of droplets, is introduced into an aqueous crosslinking solution, which is commonly a soluble salt such as calcium chloride (Figure 5a). Crosslinking ions quickly diffuse into the “sol” phase. As a result, cations distribution within the gel is heterogeneous, being less concentrated in the inner parts of the droplets. This gradient is controlled by the diffusion rate of the crosslinking agent [6,48,49].

Internal gelation mechanisms involve the incorporation of an inactive form of the crosslinking agent within the “sol” phase. For example, insoluble calcium salts such as calcium oxalate, tartate, phosphate, carbonate and citrate are usually used as internal calcium source (Figure 5b). Cations release and crosslinking activation is performed through controlled alterations of the system properties such as pH fluctuation or ion solubility [48]. Hence, homogeneous gels with uniform ion distributions are obtained [10]. However, they are often soft and prone to be clustered [24,54].




1

2 **Figure 5:** Schematic representation of (a) external and (b) internal gelation

3 Alginate can also interact with oppositely charged polyelectrolytes and produce hydrogels [41].
 4 Electrostatic attraction between the anionic groups of alginates and the cationic groups of
 5 polycations leads to polyelectrolyte complexation. This approach is usually coupled with
 6 ionotropic gelation [44]. Crosslinking cations reinforce the polyelectrolyte complex [6].

7 Beads obtained through polyelectrolyte complexation can be produced *via* layer-by-layer
 8 deposition (LbL) (Figure 6). It results in alternated layers of oppositely charged polyelectrolytes
 9 sequentially arranged which surround the core material [55]. Some polyelectrolytes that have
 10 been applied in combination with alginate are chitosan [56] and poly-L-lysine [57].



11

12 **Figure 6:** Schematic layer-by-layer deposition

13 Ionotropic gelation is a simple, fast and cost-effective process. It is performed under mild
 14 conditions [6,24,44]. For polyelectrolytes complexation, complexation promoters are not needed
 15 and thus, further purification processes are not required [6].

16 Alginate gelation may occur as well by photo-crosslinking [58], gamma irradiation [59] or by a
 17 combination of these methods with ionotropic crosslinking. In addition, alginate can be
 18 covalently crosslinked by means of agents as glutaraldehyde [60,61] or poly(ethylene glycol)-
 19 diamine [62]. However, these are not as safe as ionic crosslinking for biomedical applications
 20 [45].

21 **3. Alginate hydrogels application in cancer therapy**

22 **3.1 Benefits of alginate for biomedical applications**

23 Alginate has been applied by many industries such as food, textile and paper-printing, as well
 24 as in agriculture, aquaculture and industrial waste-water treatment [8,49,63,64]. For example,
 25 recently it was patented the encapsulation of fungal microsclerotia such as *Metarhizium* spp.

1 within alginate. The patent 16/960413 teaches that alginate enhances the efficacy and stability
2 of encapsulated entomopathogenic fungi towards a variety of insects.

3 Alginate has been employed as well in fish and crustacean's vaccines. The invention
4 KR2019/017275 discloses the formulation of an acid-treated low-molecular-weight alginic acid
5 and an attenuated microorganism for oral vaccination. It addresses issues such as the
6 improvement of water quality in farms and costs lowering. Also the patent 16/062445 teaches
7 several methods for removing organic acid anions, heavy metal ions and thermally degraded
8 organic products from a liquid by means of calcium alginate-based adsorbents.

9 In addition, the patent WO/2020/118080 discloses a novel alginate-based fiber. This is made of
10 alginate, cellulose and a polyol plasticizer, such as glycerol, and it is an innovative alternative to
11 petrochemical based textile polymers.

12 Certainly, alginate is particularly valuable for the biomedical field. For example, it has been used
13 to provide dressings with antimicrobial properties. The patent EP3660191A4 discloses a novel
14 method to manufacture antimicrobial alginate fibers. It overcomes technical challenges such as
15 the cancellation of active compound's antimicrobial activity.


16 Furthermore, the United States Patent 9421220 discloses an alginate-based anti-cancer
17 formula for the treatment of colorectal cancer. It comprises an iron chelator and allows selective
18 therapeutic action. Other innovative anti-cancer formulation is described in the patent
19 KR2020/004875. It teaches low molecular weight alginic acid as active ingredient together with
20 an anticancer adjuvant as a method for preventing or treat cancer.

21 Not only is alginate employed as therapeutic agents' carrier, but also as 3-D scaffold for tissues
22 engineering and cell culture substrate, among others. For instance, the invention
23 US2020/031877 provides a thrombin-free plasma-alginate gel to support stem cell growth. The
24 material includes fibrin, alginate and calcium. Also modified alginates have been patented for
25 pancreatic islet cells encapsulation, especially useful for diabetes treatment. Besides, the patent
26 CN2018/109187 discloses a formulation based on alginate hydrogel so as to preserve cellular
27 activity of cell solutions during storage at low temperatures. The preservation solution is
28 composed by sodium alginate, calcium chloride and hyaluronic acid.

29 Doubtlessly, alginate presents many advantages that make it especially useful for therapeutic
30 agents' encapsulation (Figure 7): it is abundant in nature and derive from renewable sources
31 [45,47]; it is inexpensive and commonly available [24,53].

32 Owing to the hydroxyl and carboxyl groups of each G and M residue, alginate is highly reactive.
33 Chemical functionalization has been widely explored and a wide variety of derivatized alginates
34 is available, which enables tailoring hydrogels properties accurately for specific applications
35 [43,47].

36 Alginate meets the safety requirements concerning to biocompatibility, biodegradation and
37 toxicity. Given its inert nature, it is not irritant, toxic nor immunogenic [8,24,42,47,49]. Although
38 the human organism does not synthesize specialized enzymes for it, alginate biodegradation
39 has been proved [8,24,42,45] . What's more, disintegration does not cause any harmful effect
40 on genetic information nor cytotoxicity. Alginates whose molecular weight is lower than 50 kDa
41 are effectively removed by kidneys [44].



1
2 **Figure 7:** Benefits of alginate for biomedical applications

3 **3.2 Alginate-based hydrogels as delivery system of anticancer therapeutic**
4 **compounds**

5 Alginate beads protect encapsulated compounds from the environment and improve their
6 bioavailability [45,65]. Encapsulation enables the sustained and local delivery of loaded factors.
7 Therefore, higher concentrations are achieved in targeted parts of the organism with minimal
8 side effects at undesired places.

9 Ionotropic gelation is the most employed method to produce alginate capsules [43,46]. Hence,
10 encapsulation takes place in an aqueous medium, under mild conditions and with non-toxic
11 solvents involved [66]. Calcium is the most commonly used cross-linking agent.

12 Encapsulated compounds are released through matrix degradation or diffusion. The delivery
13 rate rises when alginate matrix swells. For instance, sodium alginate hydrogels cross-linked with
14 CaCl_2 swell in the presence of Na^+ ions; afterwards ion exchange occurs and electrostatic
15 repulsive forces increase. Hence, surface pore size extends and release rate boosts [24,67,68].
16 Neutral and basic pH values also produce beads swelling and destabilization. On the contrary,
17 acid pH values yield to alginate carboxylic moieties protonation and beads shrinkage. Most of
18 the times, the release mechanism is a combination of diffusion and matrix degradation [24]:
19 when beads matrix swells, active compounds diffuse and surface dissolves.

20 **3.2.1 Alginate-based hydrogels as drug delivery systems**

21 Recent studies aim to encapsulate chemotherapeutic drugs within alginate matrix following
22 different methodologies. For instance, Kwon et al. prepared redox-responsive cystamine-loaded
23 alginate microspheres by emulsification followed by ionotropic gelation (Fig. 8a) [69], whereas
24 Lin et al. encapsulated astaxanthin (AST), which is a carotenoid with powerful anti-oxidative and
25 anti-inflammatory properties [70], by means of extrusion followed by ionotropic gelation (Fig. 8b)
26 [71].




Figure 8: Scheme of beads production through (a) extrusion and (b) emulsification method

The methodology to encapsulate the same drug may differ too. For example, not only has AST been encapsulated through extrusion [71] but also, by double emulsion. Such is the case of Zhang et al. who employed this technique so as to produce astaxanthin-loaded calcium alginate microspheres [72]. The obtained beads demonstrated the efficient inhibition of hepatoma HepG2 cancer cells. Generally, the size of beads obtained through extrusion is considerably larger than when obtained by emulsification-gelation.

Among other chemotherapeutic drugs that have been encapsulated within alginate matrix is arsenic trioxide (AOT), which is usually employed for the treatment of acute promyelocytic leukemia and advanced primary liver cancer. Lian et al. prepared AOT-loaded alginate capsules by ionotropic gelation and further coated them with red blood cell membrane [73]. *In vivo* studies with human liver cancer SMMC-7721 cells-bearing mice pointed the relieve of AOT systemic toxicity while anti-tumor effects improved.

Besides, Boi et al. encapsulated doxorubicin hydrochloride (DOX)-loaded microvoids delimited by a dextran sulfate sodium salt and poly-L-arginine hydrochloride within alginate hydrogels through extrusion followed by ionotropic gelation [51]. DOX is a widely employed antitumor agent for the treatment of diverse solid tumor types such as leukemia, aggressive lymphoma, ovarian, breast, stomach, lung, and bladder [74]. The capsules' cytotoxicity was proved on human breast adenocarcinoma MCF-7 cells. With this approach Boi et al. achieved a sustained and slower release rate compared to free DOX-loaded alginate beads.

Drug release kinetics highly depend on the interaction between alginate and the loaded therapeutic compound, which is governed by electrostatic forces [63]. Given the anionic nature of alginate across a wide range of pH values, it effectively interacts with positive charged molecules. Although encapsulation of anionic drugs is also possible, they are faster released [49]. If chemical interactions are weak, the release rate is mainly controlled by the nature of the therapeutic agents [47]. Generally, hydrophilic compounds diffuse quicker through the alginate matrix than hydrophobic compounds [40,63]: the reason is that hydrophobic drug-loaded alginate beads do not swell as much as hydrophilic ones do. For this reason, some encapsulation strategies include alginate modification so as to improve the affinity for the loaded active compound. For example, Jia et al. prepared DOX-loaded nanoparticles based on PEGylated oxidized alginate crosslinked with fluorescent carbon dots [75]. They aimed at pH-responsive DOX delivery in acidic environment. DOX was linked to PEGylated oxidized alginate nanoparticles through acid-labile "Schiff-Base" conjugation. Cytotoxicity and cellular uptake assays with ovarian cancer SKOV3 cells evidenced pH-triggered and nucleus-targeted DOX delivery. Thus, DOX anticancer effects were enhanced. Moreover, the fluorescence

1 competence of the nanoparticles permitted their application for imaging-guided drug delivery.
2 Besides, Talebian et al. modified alginate hydrogels in order to achieve affinity-controlled
3 release of DOX and gemcitabine [76]. Dopamine-modified alginate was part of the core and
4 improved chemotherapeutic agents' affinity, whereas the shell was composed by
5 methacrylated-alginate. A slower drug release was evidenced compared to unmodified alginate
6 delivery system. DOX- and dual-loaded capsules considerably inhibited tumor growth of
7 pancreatic cancer cell lines MIA PaCa-2, PANC-1, and BxPC3. As well Rezk et al. conjugated
8 alginate with polydopamine [77]. They aimed at pH-responsive delivery of bortezomib as drug
9 release studies confirmed.

10 Alginate has been also modified in order to promote targeted therapeutic effect. For instance,
11 Sarika et al. produced galactosylated alginate-curcumin micelles to enhance hepatocytes
12 affinity [78]. Curcumin is a polyphenol with a well-known anti-inflammatory and antioxidant
13 capacity due to its potent free radicals scavenging activity [79]. Results pointed the galactose
14 moiety to enable a selective curcumin release to human liver carcinoma HepG2 cells. Alginate
15 functionalization improved curcumin cellular uptake, accumulation and targeted cytotoxic effects
16 against HepG2 cells.

17 Despite anticancer drug-loaded alginate hydrogels are effective delivery systems, additional
18 materials often constitute the alginate-based matrix. Alginate can complex other polyelectrolytes
19 such as polysaccharides and proteins. For example, Sohail et al. studied the feasibility of
20 chitosan and alginate capsules for the delivery of amygdalin [80]. Chitosan is a natural
21 polysaccharide that has been widely applied for encapsulation purposes both alone and in
22 combination with alginate and other components. When amygdalin is hydrolyzed by
23 glucosidases, it gives rise to hydrocyanic acid, which has both antitumor and anti-inflammatory
24 properties [81]. In this study, beads were prepared through LbL technique (Figure 6). Assays
25 with lung cancer H1299 cells evidenced an increased amygdalin cellular uptake and
26 cytotoxicity.

27 Further investigation teams have employed chitosan-alginate formulations for the encapsulation
28 of anticancer agents. Such is the case of Alsmadi et al. who produced a delivery system for the
29 intratracheal administration of cisplatin (CDDP) [82]. CDDP is a chemotherapeutic drug that
30 comprises a platinum atom. In spite of its high toxicity, it has been employed for several years
31 and it is still in use. *In vivo* toxicity tests demonstrated the success of the CDDP delivery
32 system. Both the CDDP toxicity and the mortality rate of rats greatly decreased after
33 intratracheal administration.

34 Apart from chitosan, other natural polysaccharides have been used together with alginate for
35 chemotherapeutic drugs encapsulation. For instance, Hassani et al. employed Gum Arabic for
36 the encapsulation of curcumin [83]. The anticancer capacity of the system was characterized in
37 diverse cancer cell lines: human liver cancer HepG2, human colon cancer HT29, human breast
38 cancer MCF-7 and human lung cancer A549 cells. Results pointed the higher toxicity of
39 curcumin-loaded beads compared to free curcumin. In addition, Upadhyay et al. prepared
40 microbeads based on a formulation of locust bean gum and sodium alginate [52]. In this assay,
41 aluminum chloride was employed as the cross-linking agent. Beads were loaded with
42 capecitabine. The formulation was further optimized for the treatment of colonic tumors.
43 Pharmacokinetic parameters improved after oral administration to healthy rats. Drug release
44 occurred in a controlled manner. Cytotoxicity assays with human colon cancer HT-29 cells
45 confirmed a higher reduction of tumor growth compared to free capecitabine.

46 Synthetic polymers have also been applied together with alginate for encapsulation purposes.
47 Such is the case of PVA, which was used to encapsulate green tea polyphenols [84] and 5-
48 fluorouracil (5FU) [85] by Chen et al. and Dalei et al. respectively. Besides, Hosseinzadeh et al.
49 designed a brain implant made of temozolomide (TMZ)-loaded PLGA microspheres embedded
50 within an alginate matrix for glioblastoma therapy [86]. This would enable the precise location of
51 the delivery system at the tumor site and the sustained TMZ release. The implant – GlioMesh
52 was produced by means of microextrusion 3D-printing technology and ionotropic gelation.
53 Cellular viability tests on glioblastoma U-251 MG and U-87 MG cells, western blotting and
54 mitochondrial damage evaluation evidenced the greater efficiency of the novel delivery system
55 over free TMZ.

1 A different strategy involves alginate complexation with proteins. In 2020 Elbially et al. prepared
2 capsules of DOX-loaded caseinate nanoparticles with alginate shell [87]. The presence of
3 casein makes possible the encapsulation of both hydrophobic and hydrophilic drugs. Although
4 free DOX is barely internalized by cancer cells, alginate-coated beads ameliorated anticancer
5 effectiveness of DOX in Ehrlich carcinoma-bearing mice.

6 Moreover, alginate have been employed in combination with both polysaccharides and proteins.
7 For instance, Shen et al. employed alginate-chitosan multilayers as coating material of DOX-
8 loaded bovine serum albumin (BSA)-gel-capsules [61]. BSA enables pH-sensitive drug delivery
9 since it triggers DOX release just in acidic environments, such as tumor microenvironment.
10 Alginate-chitosan DOX-loaded BSA-gel-capsules were injected within the tumor of MCF-7/ADR
11 cells xenografted mice, a breast cancer model. Both DOX concentration and retention time at
12 the injection site improved.


13 Alginate allows smart delivery, which is the controlled release of encapsulated factors triggered
14 by a stimulus. This can be a pH fluctuation [61,77,88,89], a particular temperature [90], a
15 magnetic field [91,92] ultrasound [93] or redox potential [69]. For example, Xing et al. employed
16 CaCO_3 nanoparticles, which are especially sensitive to pH, as intelligent carriers [88]. These
17 were loaded with DOX and coated with both alginate and chitosan by means of LbL technology.
18 *In vitro* studies with human cervical cancer HeLa cells evidenced a pH-sensitive DOX release.
19 Besides, Rezk et al. employed alginate polydopamine hydrogels to achieve pH-responsive
20 bortezomib (BTZ) delivery [77]. They took advantage of the dissociation of catechol group that
21 bound polydopamine to BTZ at acidic pH, to control the precise BTZ release at tumor's
22 microenvironment. Release profile studies proved the success of the delivery system.

23 Wei et al. also prepared a smart delivery system composed by DOX-loaded gelatin core and
24 alginate-polydopamine (PDA) shell, which has a strong photothermal conversion effect [90]. The
25 effect of the hydrogels on breast cancer 4T1 cells was studied. When irradiated with near
26 infrared light, PDA increased core material temperature and promoted DOX diffusion. In
27 addition, Yun et al. combined sodium alginate with graphene oxide for the development of an
28 electro- and pH-sensitive drug carrier [89]. The loaded drug was methotrexate. *In vitro* release
29 kinetics studies proved the electro- and pH-responsive methotrexate delivery.

30 Magnetic beads suppose an attractive approach for controlled drug release since they enable a
31 precise and on-demand delivery by means of a magnetic field. For instance, Song et al.
32 employed Fe_3O_4 as the magnetic compound, together with alginate and chitosan multilayers, for
33 the targeted delivery of curcumin [91]. Therefore, higher cellular internalization and cytotoxicity
34 were achieved on breast cancer MDA-MB-231 cells compared to free curcumin. Moreover,
35 Amani et al. included to the magnetic curcumin-loaded alginate Fe_3O_4 composite, BSA and
36 poly((3-acrylamidopropyl)trimethylammonium chloride) [92]. Curcumin stabilization was
37 achieved as well as a controlled drug release under acidic pH.

38 Besides, Baghbani et al. coated with alginate multifunctional perfluorocarbon nanoemulsions;
39 namely, perflourohexane (PFH) [93]. Not only act perfluorocarbon nanoemulsions as
40 ultrasound-responsive passive-targeted carriers but also, as ultrasound-responsive imaging
41 contrast agents. DOX-loaded alginate-stabilized PFH nanodroplets were prepared through
42 nanoemulsion followed by ionotropic gelation. Ultrasound responsivity assays evidenced the
43 DOX release triggered after sonication with 28 kHz therapeutic ultrasound. *In vivo* studies with
44 breast cancer 4T1 cells-bearing mice demonstrated the total tumor elimination.

45 Sometimes, alginate-based delivery systems integrate different therapeutic agents. For
46 example, Wu et al. produced a hydrogel through the combination of previously cross-linked
47 composites (Figure 9) [94]. One composite included peptides (Pept) and cisplatin (CDDP)
48 whereas the other comprised alginate (AlgNP) and irinotecan (IRN). The resulting hydrogel
49 aimed at the differential release of CDDP and IRN. Its effectivity was tested in pulmonary
50 adenocarcinoma A549 cells and in A549 cells xenografted mouse model. Temporal dual drug
51 release was achieved. This strategy supposes a great improvement for combination therapy
52 since it promotes synergistic therapeutic effects.



1

2 **Figure 9:** Schematic representation of nanocomposite hydrogel produced via double-
3 crosslinking methodology for differential drug release in combination therapy [94]. Pept refers to
4 a peptide whose sequence consisted of 2-Naphthylacetic acid-Phe-Phe-Tyr-Glu-Arg-Gly-Asp.
5 Non-covalent coordination bonds were formed between cisplatin (CDDP) and Pept, which
6 served as the hydrogel matrix. Irinotecan-loaded alginate nanoparticles (AlgNP/IRN) were
7 prepared *via* water-in-oil-in-water (w/o/w) emulsion. AlgNP/IRN incorporation into the hydrogel
8 matrix was possible through electrostatic interactions. The figures were adopted with permission
9 from Wu, C.; Liu, J.; Zhai, Z.; Yang, L.; Tang, X.; Zhao, L.; Xu, K.; Zhong, W. Double-
10 crosslinked nanocomposite hydrogels for temporal control of drug dosing in combination
11 therapy.

12 In addition, Ibrahim et al. incorporated within alginate matrix both tamoxifen and silver
13 nanoparticles [95,96], whose anticancer activity against colon tumors had been previously
14 confirmed [97]. *In vitro* studies on breast cancer MCF-7 cells evidenced an enhanced anticancer
15 effect, which was associated to an intensified production of reactive oxygen species (ROS), the
16 down regulation of survival oncogenic genes, and cellular cycle arrest in G2/M phase.
17 Furthermore, folic acid conjugation in particles' surface significantly improved the composite
18 accumulation within the breast tumor cells.

19 Combination therapy can also involve, apart from chemotherapy, thermotherapy and
20 radiotherapy. For instance, Alamzadeh et al. prepared an alginate hydrogel co-loaded with
21 cisplatin and gold nanoparticles (AuNPs) [98]. AuNPs transform laser irradiation energy into
22 heat and additionally, they make tumor cells more sensitive to radiation. The system was tested
23 on human mouth epidermal carcinoma KB cells and resulted in the synergistic effect of
24 chemotherapy, photothermal therapy and radiotherapy. Anticancer effects were enhanced and it
25 would enable the decrease of drug and radiation dose.

26 3.2.1.1 Alginate-based hydrogels for oral drug delivery and colorectal cancer therapy

27 Several trials aim at the development of alginate-based oral delivery systems. Alginate
28 bioadhesiveness and mucoadhesiveness, as well as its proved biocompatibility, are especially
29 valuable properties for adhesive tablets formula. These can be easily introduced within the
30 organism through a minimal invasive manner.

31 Alginate mucoadhesiveness is due to the interaction with glycoproteins of the gastrointestinal
32 (GI) tract, what prolongs GI residence time and drug release. As a result, the bioavailability of
33 encapsulated factors and the mechanism of action enhance [43]. In addition, alginates have
34 been categorized by the U.S. Food and Drug Administration (US-FDA) as "Generally Referred

1 As Safe” (GRAS) material. This characterization allows an easier translation of innovative
2 outcomes from bench to bedside [43].

3 Moreover, the ability of alginate beads to swell or shrink in response to pH makes them a
4 potentially successful oral delivery vehicle. In the stomach, at low pH values, beads shrink and
5 protect the encapsulated compounds. Across the intestine, pH increases and beads swell.
6 Beads’ surface porosity rises [47] and beads destabilize. Hence, loaded compounds are
7 released [6,43,68].


8 For example, Bautista et al. developed an oral delivery system based on zein-alginate
9 complexes for the encapsulation of limonin and nomilin [99]. Zein was known to provide beads
10 with heat and water resistance and hence, to improve encapsulated compound’s bioavailability.
11 Beads’ stability was proved *in vitro* with simulated gastric fluids. Encapsulated compounds’
12 release was performed in simulated intestinal environment. In addition, both limonin and nomilin
13 kept their chemopreventive bioactivities, namely free radical-scavenging and anti-angiogenic
14 activity. Besides, Kiaei et al. prepared an alginate-pectin biocomposite for the encapsulation of
15 folic acid [100]. Pectin was added so as to improve beads’ stability in gastric environment. Also
16 burst release of folic acid in stimulated GI fluids was prevented. Both approaches evidenced the
17 potential of alginate as oral drug vehicle. For these reasons, alginate-based hydrogels are
18 notably useful for the treatment of GI diseases through oral drug administration.

19 The International Agency for Research on Cancer places colorectum cancer in the top 3 of the
20 most common types of tumor. Only in 2018 it supposed the 10.2 % of the new cases diagnosed
21 to females and the 10.9 % diagnosed to males [1]. According to Global Cancer Statistics data,
22 in 2018 the 9.2 % of cancer deaths were related to colorectal cancer and 881000 people died
23 because of it [3]. In order to prevent colorectum carcinogenesis, Wang et al. prepared an oral
24 colon-targeted delivery system composed of alginate and chitosan [56]. Both natural polymers
25 were chosen for their mucoadhesive properties. Beads were loaded with icariin, whose
26 protective and anti-inflammatory functions are well established. Studies in rats with induced
27 colonic mucosal injury showed an increased colonic residence time and icariin release in the
28 colon. Mucosal damage was reduced and hence, colon-protective effects were achieved.

29 As a way to develop an efficient colorectal cancer treatment, Sarangi et al. encapsulated
30 naproxen within a matrix of alginate and Assam Bora rice starch [101]. Beads were extra coated
31 with Eudragit S100, an enteric polymer known to improve colon targeting. Indeed, all *in vitro*, *ex*
32 *vivo* and *in vivo* studies proved the colon-targeted effects of the oral delivery system.

33 Alginate functionalization has been broadly exploited for targeted delivery. It involves the
34 inclusion of ligands within the alginate matrix so as to enhance beads’ therapeutic effect [44].
35 For instance, Raza et al. incorporated chondroitin sulphate in 5-FU-loaded sodium alginate
36 beads for selective colon delivery [102]. Chondroitin sulphate is commonly found in biological
37 tissues and its accumulation within tumor stroma has been proved. *In vitro* characterization
38 studies pointed this approach as a potential colonic targeted 5-FU vehicle when orally
39 administered.

40 Folate has been widely employed for alginate functionalization. The reason is because different
41 types of cancer cells over-express folate receptors. Not only enables folate targeted receptor-
42 mediated endocytosis but also it promotes ligand-activated drug delivery and cellular
43 accumulation [103]. With this aim, Rajpoot et al. attached folic acid (FA) to solid lipid
44 nanoparticles (SLNs) loaded with irinotecan hydrochloride trihydrate (IHT) [104]. The composite
45 was coated with alginate and an additional Eudragit S100 layer (Figure 10). The effectivity of
46 the oral delivery system was demonstrated by *in vitro* cytotoxicity studies on COLO205 cells as
47 well as on HT29 cells xenografted mice, both human colon cancer cell lines. Enhanced targeted
48 anticancer effects for colorectal cancer treatment were evidenced.



1

2 **Figure 10:** Schematic preparation of folic acid (FA)-grafted solid lipid nanoparticles (SLNs)
 3 bearing irinotecan hydrochloride trihydrate (IHT) and encapsulated in alginate matrix coated
 4 with Eudragit S100.

5 **3.2.2 Alginate-based hydrogels as protein delivery systems**

6 Alginate has been also employed as a vehicle for therapeutic proteins delivery. Given that
 7 ionotropic gelation is performed under mild conditions, adverse effects on protein structure and
 8 denaturalization are minimum [66]. In 2016, Sudareva et al. encapsulated superoxide dismutase
 9 (SOD), a therapeutic antioxidant enzyme [105]. The delivery system consisted of SOD-loaded
 10 calcium carbonate cores coated with alginate and gelatin A. In order to avoid protein
 11 degradation after oral administration, the trypsin inhibitors ovomucoid and soybean inhibitor
 12 were included. The oral delivery system proved to protect SOD activity in simulated intestinal
 13 fluids in presence of trypsin.

14 Similarly, Mahidhara et al. encapsulated iron-saturated bovine lactoferrin (isLF)-loaded calcium
 15 phosphate cores within a multilayer shell of chitosan and alginate [106]. Iron saturation have
 16 been pointed to enhance LF anticancer action. *In vitro* assays with breast cancer MDA-MB-231
 17 cells demonstrated cellular uptake and anticancer effects. In addition, effective antitumor activity
 18 was confirmed after oral administration to MDA-MB-231 cells-bearing mice, a breast cancer
 19 xenograft model. What's more, none of the mice fed with isLF beads suffered from breast tumor
 20 recurrence whereas not fed mice did.

21 **3.2.3 Alginate-based hydrogels as nucleic acid delivery systems**

22 Gene therapy involves the release of genetic information. Hence, nucleic acid-loaded alginate
 23 beads may transfect adjacent cells so as to promote therapeutic proteins synthesis or to block
 24 cancer-related genes [63]. For example, Goldshtein et al. prepared a plasmid DNA (pDNA)
 25 carrier through the complexation of nucleic acids with alginate sulphate in presence of calcium
 26 ions [107]. The pDNA encoded for Diphtheria Toxin Fragment A (DT-A), which has intracellular
 27 toxic effects. It inhibits the synthesis of proteins, what results in cell death. Therefore, it is an
 28 appropriate reporter gene of cellular uptake. The efficiency of pDNA-loaded alginate beads for
 29 cancer gene therapy was proved in breast cancer MDA-MB-231 cells.

30 Besides, Rostami et al. encapsulated small interfering RNA (siRNA) for the dual inhibition of
 31 S1PR1 (S1P/sphingosine-1-phosphate receptor 1) and GP130 (glycoprotein 130) synthesis
 32 [108]. They aimed to stop cancer progression. siRNA was confined within an alginate-
 33 conjugated trimethyl chitosan matrix. The transfection efficiency was tested in different cancer
 34 cell lines: breast cancer 4T1 cells, melanoma B16-F10, and colon cancer CT26 cells. Cellular
 35 uptake and the blockage of cancer progression signaling pathways were demonstrated.
 36 Processes such as cell proliferation, angiogenesis, tumor cells survival and metastasis were
 37 effectively suppressed.

38 **3.2.4 Alginate-based hydrogels as cell delivery systems**

39 Alginate is the most employed biopolymer for cell encapsulation [42,45]. It acts as a
 40 semipermeable membrane that allows bidirectional transport of molecules. Nutrients and
 41 oxygen are allowed in whereas cellular waste is removed from the cellular environment [50].
 42 Given the high surface / volume ratio, nutrient supply and gas exchange are enhanced [45].

43 Once introduced within an organism, encapsulated cells provide continuous synthesis of active
 44 compounds [11]. Not only enables cell therapy longer and sustained supply of therapeutic
 45 compounds but also, more complex release profiles [109]. Therapeutic agents such as small
 46 molecules and proteins are able to diffuse through the alginate layer [110]. Nevertheless,
 47 antibodies passage is impeded [109]. Alginate keeps encapsulated cells immunoisolation and

1 reduces the risk of rejection. As a result, co-administration of immunosuppressive therapies
2 might be unnecessary [111]. Any negative effect has not been reported after alginate hydrogels
3 transplant. These do not need to be removed from the host's organism because they are
4 biodegradable and biocompatible [11].

5 Alginate hydrogels produced through ionotropic gelation offer further advantages. Hydrogel
6 manufacturing under mild conditions preserves cellular integrity and viability. It guarantees
7 cellular functionality and therapeutic factor's delivery. Moreover, fast alginate gelation reduces
8 the time of cell manipulation.

9 Biological and mechanical features as well as the high-water content of alginate hydrogels
10 provide cells with a suitable niche, similar to the natural extracellular matrix. In addition, physico-
11 chemical properties can be tailored for specific cell types requirements [45].

12 For instance, Saenz del Burgo et al. encapsulated genetically modified human HEK-293 cells
13 within alginate-poly-L-lysine matrix [112]. Cultured cells secreted recombinant bispecific
14 antibodies (bsAbs): anti-CEA (carcinoembryonic antigen) x anti-CD3. These bsAbs bound
15 tumor-associated CEA and simultaneously promoted peripheral blood lymphocytes activation.
16 Results evidenced the potential of this approach to eradicate CEA expressing tumor cells
17 through local T-cell activation.

18 In regards to *in vivo* studies, Johansson et al. encapsulated genetically modified human
19 glioblastoma BHK cells within alginate [113]. Cells overexpressed the extracellular part of
20 protein Lrig1 (sLrig1), which is a tumor suppressor that induces EGFR downregulation and
21 degradation. EGFR gene is commonly amplified and mutated in glioblastoma cancer cells.
22 Therefore, the obtained beads were introduced into the brain of glioma-bearing mice. Results
23 demonstrated Lrig1 inhibition of tumor growth and the improvement of mice survival.

24 A different approach involved the encapsulation of bacterial cells. Funaro et al. used alginate to
25 immobilize recombinant *E. coli* [114]. Cells were genetically modified and synthesized cytosine
26 deaminase (CD), which catalyzes the conversion of 5-fluorocytosine, a non-toxic prodrug, to 5-
27 FU. *In vitro* assays with rat 9L glioma cells proved an anticancer effect similar to that of free 5-
28 FU. However, this strategy would allow a localized 5-FU action and hence, systemic toxicity
29 could be avoided.

30 **3.3 Alginate-based hydrogels as cell culture substrate**

31 Physico-chemical characteristics of alginate hydrogels make them similar to the extracellular
32 matrices of soft biological tissues [42,45]. In addition, they hold a high-water content. Because
33 of the similarities with macromolecular-based biostructures, alginate hydrogels are employed as
34 scaffolds for cell culture and they are useful for *in vitro* studies and assays [42].

35 For instance, Mandal et al. made use of sodium alginate to study the influence of Wharton's
36 jelly-derived mesenchymal stem cells (WJMSCs) on breast cancer stem cells (CSCs), namely
37 MDA-MB-231 and MCF-7 cell lines [115]. Therefore, WJMSCs were encapsulated and
38 evaluated. Findings in gene expression and paracrine profile considerably differed whether cells
39 were seeded in a 2-D monolayer culture or in an alginate 3-D scaffold. In the 3-D hydrogels
40 WJMSCs stem cell properties remained and their therapeutic effect was enhanced. Alginate
41 hydrogels enabled a more realistic evaluation of cellular interactions in the natural tumor
42 environment. Results determined the antitumorogenic effect of WJMSCs on breast CSCs.

43 In addition, Kletzmayer et al. seeded ovarian cancer SKOV3 cells, lung cancer A549 cells and
44 prostate cancer LNCaP cells in an alginate-chitosan 3-D culture. Cells were exposed to
45 doxorubicin and paclitaxel in order to identify possible chemoresistance-associated therapeutic
46 targets [116]. After a proteomic screening, tumor-associated antigens were recognized and
47 targeting antibodies were produced. Hydrogels allowed a feasible assessment of the
48 immunotherapy effectiveness. Moreover, a more automated procedure in regards to cell
49 seeding, media and therapeutic agents supply, and cell viability test could be performed.

50 Otherwise, El-Sayed et al. enclosed *Aspergillus Fumigatus* and *Alternaria Tenuissima* in
51 calcium-alginate capsules for the production of Taxol [117]. Taxol is a therapeutic compound
52 broadly applied for cancer chemotherapy and other diseases. It is obtained from some vegetal
53 *Taxus* species and thus, its application is not sustainable nor eco-friendly. Both fungal strains

1 were capable to produce Taxol. Furthermore, the encapsulation conditions were adapted to
2 optimize Taxol productivity.

3 **3.4 Further applications of alginate-based hydrogels**

4 Alginate hydrogels have been combined with other compounds such as metals and carbon-
5 based nanomaterials to ameliorate immunosensing devices. Alginate functionalization with
6 antigens or antibodies is performed to enable signal transduction and tumor biomarkers
7 detection. Such is the example of Zhao et al. who prepared a sodium alginate-based
8 immunosensor for the detection of prostate-specific antigen (PSA) [118]. The design was a
9 sandwich-type immunoassay based on electrochemical signal transduction. The device was
10 proved to be specific and stable. It was sensible enough to determine up to 0.9 fg/ml of PSA.

11 Besides, Lee et al. developed a system to improve laparoscopic operations based on alginate
12 hydrogels loaded with human serum albumin (HAS) and indocyanine green (ICG), a dye
13 commonly applied for imaging diagnostic test [119]. The effectivity of the hydrogel as
14 fluorescent surgical marker was tested in a porcine model. It was injected into submucosal
15 spaces of the porcine stomach the fluorescent signal and persisted up to 3 days after without
16 diffusing. Therefore, this laparoscopic fluorescence imaging system was proved as a potential
17 strategy to accurately define tumor location during surgery.

18 **Conclusion**

19 In summary, this review provides an overview of alginate properties, chemical structure and
20 hydrogel formation ability by means of ionotropic gelation. Given its suitability for a broad
21 spectrum of biomedical applications, it can be said that alginate has good prospects in cancer
22 therapy and research. As we could see throughout this review, not only is it a smart vehicle for
23 anticancer drugs, proteins, nucleic acids and cell delivery but also an efficient 3-D scaffold for
24 both cell culture and immunosensing, and fluorescent surgical marker.

25 Given its ability to shrink, the mucoadhesiveness as well as the GRAS classification by the US-
26 FDA, alginate is a successful component of oral delivery systems, particularly valuable for the
27 treatment of GI tumors. In addition, the possibility of alginate functionalization and the
28 combination with other polymers allows a more accurate delivery of therapeutic compounds at
29 targeted parts of the organism.

30 Despite the fact that clinical application of alginate-based hydrogels is still limited, it is a
31 promising biomaterial for cancer treatment and research. Alginate is expected to improve
32 traditional therapies and overcome current associated drawbacks such as tumor resistance and
33 systemic toxicity. All in all, alginate hydrogels promote new encouraging opportunities for cancer
34 patients' total recovery.

35 **Supplementary Materials:**

36 **Author Contributions:** Writing—original draft preparation, Belen Reig-Vano; writing—review
37 and editing, Bartosz Tylkowski, Xavier Montané and Marta Giamberini. All authors have read
38 and agreed to the published version of the manuscript.

39 **Funding:** This work was funded by Martí i Franquès grant given to the Doctoral Program in
40 Nanoscience, Materials and Chemical Engineering of Chemical Engineering Department of
41 Rovira i Virgili University. The APC was funded by Eurecat.

42 **Acknowledgments:**

43 **Conflict of Interest:** The authors declare no conflict of interest.

44 **References**

- 45
46 [1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer
47 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
48 in 185 countries, *CA: A Cancer Journal for Clinicians* 68 (2018) 394–424.
49 <https://doi.org/10.3322/caac.21492>.
50 [2] M. Ammendola, M. Haponska, K. Balik, P. Modrakowska, K. Matulewicz, L. Kazmierski, A.
51 Lis, J. Kozłowska, R. Garcia-Valls, M. Giamberini, A. Bajek, B. Tylkowski, Stability and

- 1 anti-proliferative properties of biologically active compounds extracted from *Cistus L.* after
2 sterilization treatments, *Sci Rep* 10 (2020) 6521. [https://doi.org/10.1038/s41598-020-](https://doi.org/10.1038/s41598-020-63444-3)
3 [63444-3](https://doi.org/10.1038/s41598-020-63444-3).
- 4 [3] International Agency for Research on Cancer, Latest global cancer data, 2018.
- 5 [4] C. Pucci, C. Martinelli, G. Ciofani, Innovative approaches for cancer treatment: current
6 perspectives and new challenges, *Ecancermedicallscience* 13 (2019) 961.
7 <https://doi.org/10.3332/ecancer.2019.961>.
- 8 [5] X. Montané, A. Bajek, K. Roszkowski, J.M. Montornés, M. Giamberini, S. Roszkowski, O.
9 Kowalczyk, R. Garcia-Valls, B. Tylkowski, Encapsulation for Cancer Therapy, *Molecules*
10 25 (2020). <https://doi.org/10.3390/molecules25071605>.
- 11 [6] M.K. Mishra (Ed.), Handbook of Encapsulation and Controlled Release: Chapter 14:
12 Ionotropic Gelation and Polyelectrolyte Complexation Technique: Novel Approach to Drug
13 Encapsulation, 2016.
- 14 [7] C.Y. Wong, H. Al-Salami, C.R. Dass, Microparticles, microcapsules and microspheres: A
15 review of recent developments and prospects for oral delivery of insulin, *International*
16 *journal of pharmaceutics* 537 (2018) 223–244.
17 <https://doi.org/10.1016/j.ijpharm.2017.12.036>.
- 18 [8] Bartosz Tylkowski and Renata Jastrzb, Smart Capsules for Lead Removal from Industrial
19 Wastewater volume 17 (2017).
- 20 [9] M.N. Singh, K.S.Y. Hemant, M. Ram, H.G. Shivakumar, Microencapsulation: A promising
21 technique for controlled drug delivery, *Research in pharmaceutical sciences* 5 (2010) 65–
22 77.
- 23 [10] D. Hudson, A. Margaritis, Biopolymer nanoparticle production for controlled release of
24 biopharmaceuticals, *Critical reviews in biotechnology* 34 (2014) 161–179.
25 <https://doi.org/10.3109/07388551.2012.743503>.
- 26 [11] Bhujbal SV, de Vos P, Niclou SP, Drug and cell encapsulation: Alternative delivery options
27 for the treatment of malignant brain tumors, *Advanced drug delivery reviews* 67-68 (2014)
28 142–153. <https://doi.org/10.1016/j.addr.2014.01.010>.
- 29 [12] V. Marturano, J. Kozłowska, A. Bajek, M. Giamberini, V. Ambrogi, P. Cerruti, R. Garcia-
30 Valls, J.M. Montornes, B. Tylkowski, Photo-triggered capsules based on lanthanide-doped
31 upconverting nanoparticles for medical applications, *Coordination Chemistry Reviews* 398
32 (2019) 213013. <https://doi.org/10.1016/j.ccr.2019.213013>.
- 33 [13] A. Nasir, A. Kausar, A. Younus, A Review on Preparation, Properties and Applications of
34 Polymeric Nanoparticle-Based Materials, *Polymer-Plastics Technology and Engineering* 54
35 (2015) 325–341. <https://doi.org/10.1080/03602559.2014.958780>.
- 36 [14] M.A. Miranda, L.B. Silva, I.P.S. Carvalho, R. Amaral, M.H. de Paula, K. Swiech, J.K.
37 Bastos, J.A.R. Paschoal, F.S. Emery, R.B. dos Reis, M.V.L.B. Bentley, P.D. Marcato,
38 Targeted uptake of folic acid-functionalized polymeric nanoparticles loading glycoalkaloidic
39 extract in vitro and in vivo assays, *Colloids and Surfaces B: Biointerfaces* 192 (2020)
40 111106. <https://doi.org/10.1016/j.colsurfb.2020.111106>.
- 41 [15] H.-C. Tsai, J.-Y. Lin, F. Maryani, C.-C. Huang, T. Imae, Drug-loading capacity and nuclear
42 targeting of multiwalled carbon nanotubes grafted with anionic amphiphilic copolymers,
43 *International journal of nanomedicine* 8 (2013) 4427–4440.
44 <https://doi.org/10.2147/IJN.S53636>.
- 45 [16] C. Gong, X. Yu, B. You, Y. Wu, R. Wang, L. Han, Y. Wang, S. Gao, Y. Yuan, Macrophage-
46 cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast
47 cancer therapy, *Journal of nanobiotechnology* 18 (2020) 92.
48 <https://doi.org/10.1186/s12951-020-00649-8>.
- 49 [17] Y. Li, J. Lin, Z. Cai, P. Wang, Q. Luo, C. Yao, Y. Zhang, Z. Hou, J. Liu, X. Liu, Tumor
50 microenvironment-activated self-recognizing nanodrug through directly tailored assembly
51 of small-molecules for targeted synergistic chemotherapy, *Journal of Controlled Release*
52 321 (2020) 222–235. <https://doi.org/10.1016/j.jconrel.2020.02.025>.
- 53 [18] X. Chen, H. Qian, H. Qiao, B. Dong, E. Chen, D. Huang, T. Wang, W. Chen, Tumor-
54 Adhesive and pH-Degradable Microgels by Microfluidics and Photo-Cross-Linking for
55 Efficient Antiangiogenesis and Enhanced Cancer Chemotherapy, *Biomacromolecules* 21
56 (2020) 1285–1294. <https://doi.org/10.1021/acs.biomac.0c00049>.

- 1 [19] M.S. Gularte, R.F.N. Quadrado, N.S. Pedra, M.S.P. Soares, N.P. Bona, R.M. Spanevello,
2 A.R. Fajardo, Preparation, characterization and antitumor activity of a cationic starch-
3 derivative membrane embedded with a β -cyclodextrin/curcumin inclusion complex,
4 International journal of biological macromolecules 148 (2020) 140–152.
5 <https://doi.org/10.1016/j.ijbiomac.2020.01.104>.
- 6 [20] P. Jiang, F.J. Chaparro, C.T. Cuddington, A.F. Palmer, M.P. Ohr, J.J. Lannutti, K.E.
7 Swindle-Reilly, Injectable biodegradable bi-layered capsule for sustained delivery of
8 bevacizumab in treating wet age-related macular degeneration, Journal of Controlled
9 Release 320 (2020) 442–456. <https://doi.org/10.1016/j.jconrel.2020.01.036>.
- 10 [21] C.G. Zamboni, K.L. Kozielski, H.J. Vaughan, M.M. Nakata, J. Kim, L.J. Higgins, M.G.
11 Pomper, J.J. Green, Polymeric nanoparticles as cancer-specific DNA delivery vectors to
12 human hepatocellular carcinoma, Journal of Controlled Release 263 (2017) 18–28.
13 <https://doi.org/10.1016/j.jconrel.2017.03.384>.
- 14 [22] Y. Liu, Y. Li, D. Keskin, L. Shi, Poly(β -Amino Esters): Synthesis, Formulations, and Their
15 Biomedical Applications, Advanced healthcare materials 8 (2019) e1801359.
16 <https://doi.org/10.1002/adhm.201801359>.
- 17 [23] Z. Jin, K. Wu, J. Hou, K. Yu, Y. Shen, S. Guo, A PTX/nitinol stent combination with
18 temperature-responsive phase-change 1-hexadecanol for magnetocaloric drug delivery:
19 Magnetocaloric drug release and esophagus tissue penetration, Biomaterials 153 (2018)
20 49–58. <https://doi.org/10.1016/j.biomaterials.2017.10.040>.
- 21 [24] N.T.T. Uyen, Z.A.A. Hamid, N.X.T. Tram, N. Ahmad, Fabrication of alginate microspheres
22 for drug delivery: A review, International journal of biological macromolecules 153 (2020)
23 1035–1046. <https://doi.org/10.1016/j.ijbiomac.2019.10.233>.
- 24 [25] S.T. Minzanova, V.F. Mironov, D.M. Arkhipova, A.V. Khabibullina, L.G. Mironova, Y.M.
25 Zakirova, V.A. Milyukov, Biological Activity and Pharmacological Application of Pectic
26 Polysaccharides: A Review, Polymers 10 (2018). <https://doi.org/10.3390/polym10121407>.
- 27 [26] B.N. Matos, M.N. Pereira, M.d.O. Bravo, M. Cunha-Filho, F. Saldanha-Araújo, T. Gratieri,
28 G.M. Gelfuso, Chitosan nanoparticles loading oxaliplatin as a mucoadhesive topical
29 treatment of oral tumors: Iontophoresis further enhances drug delivery ex vivo,
30 International journal of biological macromolecules 154 (2020) 1265–1275.
31 <https://doi.org/10.1016/j.ijbiomac.2019.11.001>.
- 32 [27] B. Tian, Y. Liu, J. Liu, Cyclodextrin as a magic switch in covalent and non-covalent
33 anticancer drug release systems, Carbohydrate polymers 242 (2020) 116401.
34 <https://doi.org/10.1016/j.carbpol.2020.116401>.
- 35 [28] Di Li, T. Su, L. Ma, F. Yin, W. Xu, J. Ding, Z. Li, Dual-acidity-labile polysaccharide-di-drugs
36 conjugate for targeted cancer chemotherapy, European journal of medicinal chemistry 199
37 (2020) 112367. <https://doi.org/10.1016/j.ejmech.2020.112367>.
- 38 [29] M. Hou, W. Liu, L. Zhang, L. Zhang, Z. Xu, Y. Cao, Y. Kang, P. Xue, Responsive agarose
39 hydrogel incorporated with natural humic acid and MnO₂ nanoparticles for effective relief
40 of tumor hypoxia and enhanced photo-induced tumor therapy, Biomaterials science 8
41 (2020) 353–369. <https://doi.org/10.1039/c9bm01472a>.
- 42 [30] I.S. Bayer, Hyaluronic Acid and Controlled Release: A Review, Molecules 25 (2020).
43 <https://doi.org/10.3390/molecules25112649>.
- 44 [31] X. Sun, C. Liu, A.M. Omer, L.-Y. Yang, X.-K. Ouyang, Dual-layered pH-sensitive
45 alginate/chitosan/kappa-carrageenan microbeads for colon-targeted release of 5-
46 fluorouracil, International journal of biological macromolecules 132 (2019) 487–494.
47 <https://doi.org/10.1016/j.ijbiomac.2019.03.225>.
- 48 [32] C. Oliveira, N.M. Neves, R.L. Reis, A. Martins, T.H. Silva, A review on fucoidan antitumor
49 strategies: From a biological active agent to a structural component of fucoidan-based
50 systems, Carbohydrate polymers 239 (2020) 116131.
51 <https://doi.org/10.1016/j.carbpol.2020.116131>.
- 52 [33] H. Wei, W. Li, H. Chen, X. Wen, J. He, J. Li, Simultaneous Diels-Alder click reaction and
53 starch hydrogel microsphere production via spray drying, Carbohydrate polymers 241
54 (2020) 116351. <https://doi.org/10.1016/j.carbpol.2020.116351>.
- 55 [34] J.M. Korde, B. Kandasubramanian, Microbiologically extracted poly(hydroxyalkanoates)
56 and its amalgams as therapeutic nano-carriers in anti-tumor therapies, Materials science &

- 1 engineering C-Materials for biological applications 111 (2020) 110799.
2 <https://doi.org/10.1016/j.msec.2020.110799>.
- 3 [35] M.L. Tebaldi, A.L.C. Maia, F. Poletto, F.V. de Andrade, D.C.F. Soares, Poly(-3-
4 hydroxybutyrate-co-3-hydroxyvalerate) (PHBV): Current advances in synthesis
5 methodologies, antitumor applications and biocompatibility, *Journal of Drug Delivery*
6 *Science and Technology* 51 (2019) 115–126. <https://doi.org/10.1016/j.jddst.2019.02.007>.
- 7 [36] L. Wang, J. Du, X. Han, J. Dou, J. Shen, J. Yuan, Self-crosslinked keratin nanoparticles for
8 pH and GSH dual responsive drug carriers, *Journal of biomaterials science. Polymer*
9 *edition* (2020) 1–13. <https://doi.org/10.1080/09205063.2020.1788371>.
- 10 [37] M.T. Nazeri, S. Javanbakht, A. Shaabani, M. Ghorbani, 5-aminopyrazole-conjugated
11 gelatin hydrogel: A controlled 5-fluorouracil delivery system for rectal administration,
12 *Journal of Drug Delivery Science and Technology* 57 (2020) 101669.
13 <https://doi.org/10.1016/j.jddst.2020.101669>.
- 14 [38] R. Borlan, A.-S. Tatar, O. Soritau, D. Maniu, G. Marc, A. Florea, M. Focsan, S. Astilean,
15 Design of fluorophore-loaded human serum albumin nanoparticles for specific targeting of
16 NIH:OVCAR3 ovarian cancer cells, *Nanotechnology* 31 (2020) 315102.
17 <https://doi.org/10.1088/1361-6528/ab8b90>.
- 18 [39] S.O. Correa, X. Luo, C.B. Raub, Microfluidic fabrication of stable collagen microgels with
19 aligned microstructure using flow-driven co-deposition and ionic gelation, *Journal of*
20 *Micromechanics and Microengineering* 30 (2020) 85002. [https://doi.org/10.1088/1361-](https://doi.org/10.1088/1361-6439/ab8ebf)
21 [6439/ab8ebf](https://doi.org/10.1088/1361-6439/ab8ebf).
- 22 [40] J. Venkatesan, S. Anil, S.-K. Kim, M.S. Shim, Seaweed Polysaccharide-Based
23 Nanoparticles: Preparation and Applications for Drug Delivery, *Polymers* 8 (2016).
24 <https://doi.org/10.3390/polym8020030>.
- 25 [41] E. Henao, E. Delgado, H. Contreras, G. Quintana, Polyelectrolyte Complexation versus
26 Ionotropic Gelation for Chitosan-Based Hydrogels with Carboxymethylcellulose,
27 Carboxymethyl Starch, and Alginate Acid, *International Journal of Chemical Engineering*
28 (2018) 1–12. <https://doi.org/10.1155/2018/3137167>.
- 29 [42] Kuen Yong Lee, David J. Mooney, Alginate: Properties and biomedical applications,
30 *Progress in polymer science* 37 (2012) 106–126.
31 <https://doi.org/10.1016/j.progpolymsci.2011.06.003>.
- 32 [43] A. Sosnik, Alginate Particles as Platform for Drug Delivery by the Oral Route: State-of-the-
33 Art, *ISRN pharmaceuticals* 2014 (2014) 926157. <https://doi.org/10.1155/2014/926157>.
- 34 [44] M. Lopes, B. Abraham, F. Veiga, R. Seica, L.M. Cabral, P. Arnaud, J.C. Andrade, A.J.
35 Ribeiro, Preparation methods and applications behind alginate-based particles, *Expert*
36 *opinion on drug delivery* 14 (2017) 769–782.
37 <https://doi.org/10.1080/17425247.2016.1214564>.
- 38 [45] A. Gonzalez-Pujana, G. Orive, J.L. Pedraz, E. Santos-Vizcaino, R.M. Hernandez, Alginate
39 Microcapsules for Drug Delivery 11 67–100. https://doi.org/10.1007/978-981-10-6910-9_3.
- 40 [46] I.D. Hay, Z. Ur Rehman, A. Ghafoor, B.H.A. Rehm, Bacterial biosynthesis of alginates,
41 *Journal of Chemical Technology & Biotechnology* 85 (2010) 752–759.
42 <https://doi.org/10.1002/jctb.2372>.
- 43 [47] D. Dhamecha, R. Movsas, U. Sano, J.U. Menon, Applications of alginate microspheres in
44 therapeutics delivery and cell culture: Past, present and future, *International journal of*
45 *pharmaceutics* 569 (2019) 118627. <https://doi.org/10.1016/j.ijpharm.2019.118627>.
- 46 [48] S.N. Pawar, K.J. Edgar, Alginate derivatization: A review of chemistry, properties and
47 applications, *Biomaterials* 33 (2012) 3279–3305.
48 <https://doi.org/10.1016/j.biomaterials.2012.01.007>.
- 49 [49] S.H. Ching, N. Bansal, B. Bhandari, Alginate gel particles: A review of production
50 techniques and physical properties, *Critical reviews in food science and nutrition* 57 (2017)
51 1133–1152. <https://doi.org/10.1080/10408398.2014.965773>.
- 52 [50] R. Dorati, I. Genta, M. Ferrari, G. Vigone, V. Merico, S. Garagna, M. Zuccotti, B. Conti,
53 Formulation and stability evaluation of 3D alginate beads potentially useful for cumulus-
54 oocyte complexes culture, *Journal of microencapsulation* 33 (2016) 137–145.
55 <https://doi.org/10.3109/02652048.2015.1134691>.

- 1 [51] S. Boi, N. Rouatbi, E. Dellacasa, D. Di Lisa, P. Bianchini, O. Monticelli, L. Pastorino,
2 Alginate microbeads with internal microvoids for the sustained release of drugs,
3 International journal of biological macromolecules 156 (2020) 454–461.
4 <https://doi.org/10.1016/j.ijbiomac.2020.04.083>.
- 5 [52] M. Upadhyay, S.K.R. Adena, H. Vardhan, S.K. Yadav, B. Mishra, Development of
6 biopolymers based interpenetrating polymeric network of capecitabine: A drug delivery
7 vehicle to extend the release of the model drug, International journal of biological
8 macromolecules 115 (2018) 907–919. <https://doi.org/10.1016/j.ijbiomac.2018.04.123>.
- 9 [53] Rehm, Bernd H.A., Moradali, Fata (Ed.), Alginates and their biomedical applications,
10 Springer Singapore, 2018.
- 11 [54] Sapana P. Ahirrao, Paraag S. Gide, B. Shrivastav, Pankaj Sharma, Ionotropic Gelation: A
12 Promising Cross Linking Technique for Hydrogels, Research & Reviews: Journal of
13 Pharmaceutics and Nanotechnology 2 (2014) 1–6.
- 14 [55] K.M. Manjanna, B. Shivakumar, T.M. Pramod Kumar, Microencapsulation: An acclaimed
15 novel drug-delivery system for NSAIDs in arthritis, Critical reviews in therapeutic drug
16 carrier systems 27 (2010) 509–545.
17 <https://doi.org/10.1615/critrevtherdrugcarriersyst.v27.i6.20>.
- 18 [56] Q.-S. Wang, G.-F. Wang, J. Zhou, L.-N. Gao, Y.-L. Cui, Colon targeted oral drug delivery
19 system based on alginate-chitosan microspheres loaded with icariin in the treatment of
20 ulcerative colitis, International journal of pharmaceutics 515 (2016) 176–185.
21 <https://doi.org/10.1016/j.ijpharm.2016.10.002>.
- 22 [57] D. Qian, B. Bai, G. Yan, S. Zhang, Q. Liu, Y. Chen, X. Tan, Y. Zeng, Construction of
23 doxycycline-mediated BMP-2 transgene combining with APA microcapsules for bone
24 repair, Artificial cells, nanomedicine, and biotechnology 44 (2016) 270–276.
25 <https://doi.org/10.3109/21691401.2014.942458>.
- 26 [58] S.R. Batool, M.A. Nazeer, D. Ekinici, A. Sahin, S. Kizilel, Multifunctional alginate-based
27 hydrogel with reversible crosslinking for controlled therapeutics delivery, International
28 journal of biological macromolecules 150 (2020) 315–325.
29 <https://doi.org/10.1016/j.ijbiomac.2020.02.042>.
- 30 [59] A.I. El-Batal, F.M. Mosallam, M.M. Ghorab, A. Hanora, M. Gobara, A. Baraka, M.A.
31 Elsayed, K. Pal, R.M. Fathy, M. Abd Elkodous, G.S. El-Sayyad, Factorial design-optimized
32 and gamma irradiation-assisted fabrication of selenium nanoparticles by chitosan and
33 Pleurotus ostreatus fermented fenugreek for a vigorous in vitro effect against carcinoma
34 cells, International journal of biological macromolecules 156 (2020) 1584–1599.
35 <https://doi.org/10.1016/j.ijbiomac.2019.11.210>.
- 36 [60] G. Chen, R. Wei, X. Huang, F. Wang, Z. Chen, Synthesis and assessment of sodium
37 alginate-modified silk fibroin microspheres as potential hepatic arterial embolization agent,
38 International journal of biological macromolecules 155 (2020) 1450–1459.
39 <https://doi.org/10.1016/j.ijbiomac.2019.11.122>.
- 40 [61] H. Shen, F. Li, D. Wang, Z. Yang, C. Yao, Y. Ye, X. Wang, Chitosan-alginate BSA-gel-
41 capsules for local chemotherapy against drug-resistant breast cancer, Drug design,
42 development and therapy 12 (2018) 921–934. <https://doi.org/10.2147/DDDT.S158001>.
- 43 [62] F. Abasalizadeh, S.V. Moghaddam, E. Alizadeh, E. Akbari, E. Kashani, S.M.B. Fazljou, M.
44 Torbati, A. Akbarzadeh, Alginate-based hydrogels as drug delivery vehicles in cancer
45 treatment and their applications in wound dressing and 3D bioprinting, Journal of biological
46 engineering 14 (2020) 8. <https://doi.org/10.1186/s13036-020-0227-7>.
- 47 [63] A.D. Augst, H.J. Kong, D.J. Mooney, Alginate hydrogels as biomaterials, Macromolecular
48 bioscience 6 (2006) 623–633. <https://doi.org/10.1002/mabi.200600069>.
- 49 [64] K.P. Plant, S.E. Lapatra, Advances in fish vaccine delivery, Developmental and
50 comparative immunology 35 (2011) 1256–1262. <https://doi.org/10.1016/j.dci.2011.03.007>.
- 51 [65] B. Wang, T.O. Akanbi, D. Agyei, B.J. Holland, C.J. Barrow, Coacervation Technique as an
52 Encapsulation and Delivery Tool for Hydrophobic Biofunctional Compounds 235–261.
53 <https://doi.org/10.1016/B978-0-12-811448-3.00007-3>.
- 54 [66] W.C. Blocher, S.L. Perry, Complex coacervate-based materials for biomedicine, Wiley
55 interdisciplinary reviews. Nanomedicine and nanobiotechnology 9 (2017).
56 <https://doi.org/10.1002/wnan.1442>.

- 1 [67] C. Alvarez-Lorenzo, B. Blanco-Fernandez, A.M. Puga, A. Concheiro, Crosslinked ionic
2 polysaccharides for stimuli-sensitive drug delivery, *Advanced drug delivery reviews* 65
3 (2013) 1148–1171. <https://doi.org/10.1016/j.addr.2013.04.016>.
- 4 [68] J.P. Senna, T.N. Barradas, S. Cardoso, T.C. Castiglione, M.J. Serpe, K.G.d.H.E. Silva,
5 C.R.E. Mansur, Dual alginate-lipid nanocarriers as oral delivery systems for amphotericin
6 B, *Colloids and Surfaces B: Biointerfaces* 166 (2018) 187–194.
7 <https://doi.org/10.1016/j.colsurfb.2018.03.015>.
- 8 [69] K. Kwon, J.-C. Kim, Redox-responsive alginate microsphere containing cystamine, *Journal*
9 *of biomaterials science, Polymer edition* 27 (2016) 1520–1533.
10 <https://doi.org/10.1080/09205063.2016.1215800>.
- 11 [70] R.G. Fassett, J.S. Coombes, Astaxanthin, oxidative stress, inflammation and
12 cardiovascular disease, *Future cardiology* 5 (2009) 333–342.
13 <https://doi.org/10.2217/fca.09.19>.
- 14 [71] S.-F. Lin, Y.-C. Chen, R.-N. Chen, L.-C. Chen, H.-O. Ho, Y.-H. Tsung, M.-T. Sheu, D.-Z.
15 Liu, Improving the Stability of Astaxanthin by Microencapsulation in Calcium Alginate
16 Beads, *PLOS ONE* 11 (2016) e0153685. <https://doi.org/10.1371/journal.pone.0153685>.
- 17 [72] X. Zhang, W. Li, X. Dou, de Nan, G. He, Astaxanthin Encapsulated in Biodegradable
18 Calcium Alginate Microspheres for the Treatment of Hepatocellular Carcinoma In Vitro,
19 *Applied biochemistry and biotechnology* 191 (2020) 511–527.
20 <https://doi.org/10.1007/s12010-019-03174-z>.
- 21 [73] Y. Lian, X. Wang, P. Guo, Y. Li, F. Raza, J. Su, M. Qiu, Erythrocyte Membrane-Coated
22 Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy,
23 *Pharmaceutics* 12 (2019). <https://doi.org/10.3390/pharmaceutics12010021>.
- 24 [74] R.R. Patil, S.A. Guhagarkar, P.V. Devarajan, Engineered nanocarriers of doxorubicin: a
25 current update, *Critical reviews in therapeutic drug carrier systems* 25 (2008) 1–61.
26 <https://doi.org/10.1615/critrevtherdrugcarriersyst.v25.i1.10>.
- 27 [75] X. Jia, M. Pei, X. Zhao, K. Tian, T. Zhou, P. Liu, PEGylated Oxidized Alginate-DOX
28 Prodrug Conjugate Nanoparticles Cross-Linked with Fluorescent Carbon Dots for Tumor
29 Theranostics, *ACS Biomater. Sci. Eng.* 2 (2016) 1641–1648.
30 <https://doi.org/10.1021/acsbiomaterials.6b00443>.
- 31 [76] S. Talebian, I.K. Shim, S.C. Kim, G.M. Spinks, K.L. Vine, J. Foroughi, Coaxial mussel-
32 inspired biofibers: making of a robust and efficacious depot for cancer drug delivery,
33 *Journal of materials chemistry B* 8 (2020) 5064–5079. <https://doi.org/10.1039/d0tb00052c>.
- 34 [77] A.I. Rezk, F.O. Obiweluozor, G. Choukrani, C.H. Park, C.S. Kim, Drug release and kinetic
35 models of anticancer drug (BTZ) from a pH-responsive alginate polydopamine hydrogel:
36 Towards cancer chemotherapy, *International journal of biological macromolecules* 141
37 (2019) 388–400. <https://doi.org/10.1016/j.ijbiomac.2019.09.013>.
- 38 [78] P.R. Sarika, N.R. James, P.R.A. Kumar, D.K. Raj, Galactosylated alginate-curcumin
39 micelles for enhanced delivery of curcumin to hepatocytes, *International journal of*
40 *biological macromolecules* 86 (2016) 1–9. <https://doi.org/10.1016/j.ijbiomac.2016.01.037>.
- 41 [79] W. Liu, Y. Zhai, X. Heng, F.Y. Che, W. Chen, D. Sun, G. Zhai, Oral bioavailability of
42 curcumin: problems and advancements, *Journal of drug targeting* 24 (2016) 694–702.
43 <https://doi.org/10.3109/1061186X.2016.1157883>.
- 44 [80] R. Sohail, S.R. Abbas, Evaluation of amygdalin-loaded alginate-chitosan nanoparticles as
45 biocompatible drug delivery carriers for anticancerous efficacy, *International journal of*
46 *biological macromolecules* 153 (2020) 36–45.
47 <https://doi.org/10.1016/j.ijbiomac.2020.02.191>.
- 48 [81] Z. Song, X. Xu, Advanced research on anti-tumor effects of amygdalin, *Journal of Cancer*
49 *Research and Therapeutics* 10 Suppl 1 (2014) 3–7. <https://doi.org/10.4103/0973-1482.139743>.
- 50 [82] M.'t.M. Alsmadi, R.M. Obaidat, M. Alnaief, B.A. Albiss, N. Hailat, Development, In Vitro
51 Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous
52 Carriers Loaded with Cisplatin for Lung Cancer Treatment, *AAPS PharmSciTech* 21 (2020)
53 191. <https://doi.org/10.1208/s12249-020-01735-8>.
- 54 [83] A. Hassani, S. Mahmood, H.H. Enezei, S.A. Hussain, H.A. Hamad, A.F. Aldoghachi, A.
55 Hagar, A.A. Doolaanea, W.N. Ibrahim, Formulation, Characterization and Biological
56

- 1 Activity Screening of Sodium Alginate-Gum Arabic Nanoparticles Loaded with Curcumin,
2 *Molecules* 25 (2020). <https://doi.org/10.3390/molecules25092244>.
- 3 [84] G. Chen, L. He, P. Zhang, J. Zhang, X. Mei, D. Wang, Y. Zhang, X. Ren, Z. Chen,
4 Encapsulation of green tea polyphenol nanospheres in PVA/alginate hydrogel for
5 promoting wound healing of diabetic rats by regulating PI3K/AKT pathway, *Materials*
6 *science & engineering C: Materials for biological applications* 110 (2020) 110686.
7 <https://doi.org/10.1016/j.msec.2020.110686>.
- 8 [85] G. Dalei, S. Swain, S. Das, S.P. Das, Controlled Release of 5-Fluorouracil from Alginate
9 Hydrogels by Cold HMDSO–Plasma Surface Engineering, *ChemistrySelect* 5 (2020)
10 2168–2178. <https://doi.org/10.1002/slct.201904449>.
- 11 [86] R. Hosseinzadeh, B. Mirani, E. Pagan, S. Mirzaaghaei, A. Nasimian, P. Kawalec, S.C.
12 Silva Rosa, D. Hamdi, N.P. Fernandez, B.D. Toyota, J.W. Gordon, S. Ghavami, M. Akbari,
13 A Drug-Eluting 3D-Printed Mesh (GlioMesh) for Management of Glioblastoma, *Advanced*
14 *Therapeutics* 2 (2019) 1900113. <https://doi.org/10.1002/adtp.201900113>.
- 15 [87] N.S. Elbially, N. Mohamed, Alginate-coated caseinate nanoparticles for doxorubicin
16 delivery: Preparation, characterisation, and in vivo assessment, *International journal of*
17 *biological macromolecules* 154 (2020) 114–122.
18 <https://doi.org/10.1016/j.ijbiomac.2020.03.027>.
- 19 [88] J. Xing, Y. Cai, Y. Wang, H. Zheng, Y. Liu, Synthesis of Polymer Assembled Mesoporous
20 CaCO₃ Nanoparticles for Molecular Targeting and pH-Responsive Controlled Drug
21 Release, *Advances in Polymer Technology* (2020) 1–8.
22 <https://doi.org/10.1155/2020/8749238>.
- 23 [89] Y. Yun, H. Wu, J. Gao, W. Dai, L. Deng, O. Lv, Y. Kong, Facile synthesis of Ca²⁺-
24 crosslinked sodium alginate/graphene oxide hybrids as electro- and pH-responsive drug
25 carrier, *Materials science & engineering C: Materials for biological applications* 108 (2020)
26 110380. <https://doi.org/10.1016/j.msec.2019.110380>.
- 27 [90] X. Wei, C. Liu, Z. Wang, Y. Luo, 3D printed core-shell hydrogel fiber scaffolds with NIR-
28 triggered drug release for localized therapy of breast cancer, *International journal of*
29 *pharmaceutics* 580 (2020) 119219. <https://doi.org/10.1016/j.ijpharm.2020.119219>.
- 30 [91] W. Song, X. Su, D.A. Gregory, W. Li, Z. Cai, X. Zhao, Magnetic Alginate/Chitosan
31 Nanoparticles for Targeted Delivery of Curcumin into Human Breast Cancer Cells,
32 *Nanomaterials* 8 (2018). <https://doi.org/10.3390/nano8110907>.
- 33 [92] S. Amani, Z. Mohamadnia, A. Mahdavi, pH-responsive hybrid magnetic polyelectrolyte
34 complex based on alginate/BSA as efficient nanocarrier for curcumin encapsulation and
35 delivery, *International journal of biological macromolecules* 141 (2019) 1258–1270.
36 <https://doi.org/10.1016/j.ijbiomac.2019.09.048>.
- 37 [93] F. Baghbani, F. Moztaizadeh, J.A. Mohandesi, F. Yazdian, M. Mokhtari-Dizaji, Novel
38 alginate-stabilized doxorubicin-loaded nanodroplets for ultrasonic theranosis of breast
39 cancer, *International journal of biological macromolecules* 93 (2016) 512–519.
40 <https://doi.org/10.1016/j.ijbiomac.2016.09.008>.
- 41 [94] C. Wu, J. Liu, Z. Zhai, L. Yang, X. Tang, L. Zhao, K. Xu, W. Zhong, Double-crosslinked
42 nanocomposite hydrogels for temporal control of drug dosing in combination therapy, *Acta*
43 *biomaterialia* 106 (2020) 278–288. <https://doi.org/10.1016/j.actbio.2020.02.021>.
- 44 [95] O.M. Ibrahim, N.M. El-Deeb, H. Abbas, S.M. Elmasry, M.R. El-Aassar, Alginate based
45 tamoxifen/metal dual core-folate decorated shell: Nanocomposite targeted therapy for
46 breast cancer via ROS-driven NF-κB pathway modulation, *International journal of*
47 *biological macromolecules* 146 (2020) 119–131.
48 <https://doi.org/10.1016/j.ijbiomac.2019.12.266>.
- 49 [96] N.M.E.D. Ibrahim M, Novel Trend in Colon Cancer Therapy Using Silver Nanoparticles
50 Synthesized by Honey Bee, *Journal of Nanomedicine & Nanotechnology* 06 (2015) 1–6.
51 <https://doi.org/10.4172/2157-7439.1000265>.
- 52 [97] M. Bilal, T. Rasheed, H.M.N. Iqbal, C. Li, H. Hu, X. Zhang, Development of silver
53 nanoparticles loaded chitosan-alginate constructs with biomedical potentialities,
54 *International journal of biological macromolecules* 105 (2017) 393–400.
55 <https://doi.org/10.1016/j.ijbiomac.2017.07.047>.

- 1 [98] Z. Alamzadeh, J. Beik, M. Mirrahimi, A. Shakeri-Zadeh, F. Ebrahimi, A. Komeili, B.
2 Ghalandari, H. Ghaznavi, S.K. Kamrava, C. Moustakis, Gold nanoparticles promote a
3 multimodal synergistic cancer therapy strategy by co-delivery of thermo-chemo-radio
4 therapy, *European Journal of Pharmaceutical Sciences* 145 (2020) 105235.
5 <https://doi.org/10.1016/j.ejps.2020.105235>.
- 6 [99] G.F.M. Bautista, M.L.P. Vidallon, K.C. Salamaney, E.B. Rodriguez, Nanodelivery system
7 based on zein-alginate complexes enhances in vitro chemopreventive activity and
8 bioavailability of pomelo [*Citrus maxima* (Burm.) Merr.] seed limonoids, *Journal of Drug
9 Delivery Science and Technology* 54 (2019) 101296.
10 <https://doi.org/10.1016/j.jddst.2019.101296>.
- 11 [100] P. Kiaei Pour, I. Alemzadeh, A.S. Vaziri, A. Beiroti, Potential effects of alginate–pectin
12 biocomposite on the release of folic acid and their physicochemical characteristics, *Journal
13 of Food Science and Technology*. <https://doi.org/10.1007/s13197-020-04369-7>.
- 14 [101] M.K. Sarangi, M.B. Rao, V. Parcha, A. Upadhyay, Tailoring of Colon Targeting with
15 Sodium Alginate-Assam Bora Rice Starch Based Multi Particulate System Containing
16 Naproxen, *Starch - Stärke* (2020) 1900307. <https://doi.org/10.1002/star.201900307>.
- 17 [102] H. Raza, N.M. Ranjha, R. Razzaq, M. Ansari, A. Mahmood, Z. Rashid, Fabrication and In
18 Vitro Evaluation on 5-Fluorouracil loaded Chondroitin Sulfate-Sodium Alginate
19 Microspheres for Colon Specific Delivery, *Acta poloniae pharmaceutica* 73 (2016) 495–
20 507.
- 21 [103] P.M. Shad, S.Z. Karizi, R.S. Javan, A. Mirzaie, H. Noorbazargan, I. Akbarzadeh, H.
22 Rezaie, Folate conjugated hyaluronic acid coated alginate nanogels encapsulated
23 oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell
24 line), *Toxicol In Vitro* 65 (2020) 104756. <https://doi.org/10.1016/j.tiv.2019.104756>.
- 25 [104] K. Rajpoot, S.K. Jain, Oral delivery of pH-responsive alginate microbeads incorporating
26 folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against
27 colorectal cancer: A dual-targeted approach, *International journal of biological
28 macromolecules* 151 (2020) 830–844. <https://doi.org/10.1016/j.ijbiomac.2020.02.132>.
- 29 [105] N. Sudareva, O. Suvorova, N. Saprykina, A. Vilesov, P. Bel'tyukov, S. Petunov, Alginate-
30 containing systems for oral delivery of superoxide dismutase. Comparison of various
31 configurations and their properties, *Journal of microencapsulation* 33 (2016) 487–496.
32 <https://doi.org/10.1080/02652048.2016.1206146>.
- 33 [106] G. Mahidhara, R.K. Kanwar, K. Roy, J.R. Kanwar, Oral administration of iron-saturated
34 bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on
35 iron and calcium metabolism, *International journal of nanomedicine* 10 (2015) 4081–4098.
36 <https://doi.org/10.2147/IJN.S75877>.
- 37 [107] M. Goldshtein, S. Shamir, E. Vinogradov, A. Monsonego, S. Cohen, Co-assembled Ca²⁺-
38 Alginate-Sulfate Nanoparticles for Intracellular Plasmid DNA Delivery, *Molecular Therapy -
39 Nucleic Acids* 16 (2019) 378–390. <https://doi.org/10.1016/j.omtn.2019.03.006>.
- 40 [108] N. Rostami, A. Nikkhoo, Y. Khazaee-Poul, S. Farhadi, M. Sadat Haeri, S. Moghadaszadeh
41 Ardebili, N. Aghaei Vanda, F. Atyabi, A. Namdar, M. Baghaei, N. Haghnavaz, T. Kazemi,
42 M. Yousefi, G. Ghalamfarsa, G. Sabz, F. Jadidi-Niaragh, Coinhibition of S1PR1 and
43 GP130 by siRNA-loaded alginate-conjugated trimethyl chitosan nanoparticles robustly
44 blocks development of cancer cells, *Journal of Cellular Physiology* (2020).
45 <https://doi.org/10.1002/jcp.29781>.
- 46 [109] J.K. Gandhi, E.C. Opara, E.M. Brey, Alginate-based strategies for therapeutic
47 vascularization, *Therapeutic delivery* 4 (2013) 327–341. <https://doi.org/10.4155/tde.12.163>.
- 48 [110] M. Borgogna, B. Bellich, A. Cesàro, Marine polysaccharides in microencapsulation and
49 application to aquaculture: "from sea to sea", *Marine drugs* 9 (2011) 2572–2604.
50 <https://doi.org/10.3390/md9122572>.
- 51 [111] Y.A. Mørch, I. Donati, B.L. Strand, G. Skjåk-Braek, Effect of Ca²⁺, Ba²⁺, and Sr²⁺ on
52 alginate microbeads, *Biomacromolecules* 7 (2006) 1471–1480.
53 <https://doi.org/10.1021/bm060010d>.
- 54 [112] L. Saenz del Burgo, M. Compte, M. Aceves, R.M. Hernández, L. Sanz, L. Álvarez-Vallina,
55 J.L. Pedraz, Microencapsulation of therapeutic bispecific antibodies producing cells:

- 1 immunotherapeutic organoids for cancer management, *Journal of drug targeting* 23 (2015)
2 170–179. <https://doi.org/10.3109/1061186X.2014.971327>.
- 3 [113]M. Johansson, A. Oudin, K. Tiemann, A. Bernard, A. Golebiewska, O. Keunen, F. Fack, D.
4 Stieber, B. Wang, H. Hedman, S.P. Niclou, The soluble form of the tumor suppressor Lrig1
5 potently inhibits in vivo glioma growth irrespective of EGF receptor status, *Neuro-oncology*
6 15 (2013) 1200–1211. <https://doi.org/10.1093/neuonc/not054>.
- 7 [114]M.G. Funaro, K.V. Nemani, Z. Chen, Z.M. Bhujwalla, K.E. Griswold, B. Gimi, Effect of
8 alginate microencapsulation on the catalytic efficiency and in vitro enzyme-prodrug
9 therapeutic efficacy of cytosine deaminase and of recombinant E. coli expressing cytosine
10 deaminase, *Journal of microencapsulation* 33 (2016) 64–70.
11 <https://doi.org/10.3109/02652048.2015.1115902>.
- 12 [115]S. Mandal, F. Arfuso, G. Sethi, A. Dharmarajan, S. Warriar, Encapsulated human
13 mesenchymal stem cells (eMSCs) as a novel anti-cancer agent targeting breast cancer
14 stem cells: Development of 3D primed therapeutic MSCs, *The international journal of*
15 *biochemistry & cell biology* 110 (2019) 59–69. <https://doi.org/10.1016/j.biocel.2019.02.001>.
- 16 [116]A. Kletzmayer, F. Clement Frey, M. Zimmermann, D. Eberli, C. Millan, An Automatable
17 Hydrogel Culture Platform for Evaluating Efficacy of Antibody-Based Therapeutics in
18 Overcoming Chemoresistance, *Biotechnology journal* 15 (2020) e1900439.
19 <https://doi.org/10.1002/biot.201900439>.
- 20 [117]E.-S.R. El-Sayed, A.S. Ahmed, I.A. Hassan, A.A. Ismaiel, A.-Z.A. Karam El-Din, Semi-
21 continuous production of the anticancer drug taxol by *Aspergillus fumigatus* and *Alternaria*
22 *tenuissima* immobilized in calcium alginate beads, *Bioprocess and biosystems engineering*
23 43 (2020) 997–1008. <https://doi.org/10.1007/s00449-020-02295-8>.
- 24 [118]L. Zhao, S. Yin, Z. Ma, Ca²⁺-Triggered pH-Response Sodium Alginate Hydrogel
25 Precipitation for Amplified Sandwich-Type Impedimetric Immunosensor of Tumor Marker,
26 *ACS sensors* 4 (2019) 450–455. <https://doi.org/10.1021/acssensors.8b01465>.
- 27 [119]S.S. Lee, H. Kim, D.K. Sohn, J.B. Eom, Y.S. Seo, H.M. Yoon, Y. Choi, Indocyanine green-
28 loaded injectable alginate hydrogel as a marker for precision cancer surgery, *Quantitative*
29 *Imaging in Medicine and Surgery* 10 (2020) 779–788.
30 <https://doi.org/10.21037/qims.2020.02.24>.
- 31